Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brachytherapy | 12 | 2017 | 13 | 1.000 |
Why?
|
| Esophageal Neoplasms | 10 | 2010 | 26 | 0.820 |
Why?
|
| Palliative Care | 10 | 2017 | 52 | 0.620 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 32 | 0.330 |
Why?
|
| Sarcoma, Kaposi | 2 | 2008 | 53 | 0.310 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 195 | 0.260 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2010 | 32 | 0.250 |
Why?
|
| Radiotherapy Dosage | 10 | 2015 | 13 | 0.230 |
Why?
|
| Survival Rate | 8 | 2017 | 96 | 0.200 |
Why?
|
| Middle Aged | 21 | 2015 | 3601 | 0.180 |
Why?
|
| Male | 23 | 2017 | 6754 | 0.170 |
Why?
|
| Humans | 28 | 2021 | 14537 | 0.170 |
Why?
|
| Aged | 18 | 2015 | 1740 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2015 | 8 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 239 | 0.150 |
Why?
|
| Bronchial Neoplasms | 1 | 2017 | 1 | 0.140 |
Why?
|
| Treatment Outcome | 7 | 2017 | 889 | 0.140 |
Why?
|
| Female | 19 | 2017 | 9103 | 0.140 |
Why?
|
| Prospective Studies | 6 | 2017 | 1160 | 0.140 |
Why?
|
| Neoplasms | 2 | 2008 | 147 | 0.130 |
Why?
|
| Quality of Life | 2 | 2015 | 177 | 0.130 |
Why?
|
| Airway Obstruction | 1 | 2015 | 1 | 0.120 |
Why?
|
| Adult | 17 | 2010 | 5913 | 0.120 |
Why?
|
| Prognosis | 5 | 2008 | 199 | 0.120 |
Why?
|
| Neoplasm Staging | 9 | 2006 | 50 | 0.110 |
Why?
|
| Combined Modality Therapy | 4 | 2008 | 25 | 0.110 |
Why?
|
| South Africa | 10 | 2021 | 7596 | 0.110 |
Why?
|
| Seminoma | 3 | 1996 | 3 | 0.090 |
Why?
|
| Testicular Neoplasms | 3 | 1996 | 4 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2015 | 468 | 0.080 |
Why?
|
| Antineoplastic Agents | 2 | 2006 | 62 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 45 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 163 | 0.070 |
Why?
|
| Smoking | 1 | 2008 | 100 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2006 | 9 | 0.070 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 25 | 0.070 |
Why?
|
| Cisplatin | 1 | 2006 | 5 | 0.070 |
Why?
|
| Pelvis | 1 | 2006 | 5 | 0.070 |
Why?
|
| Hemoptysis | 2 | 2017 | 4 | 0.070 |
Why?
|
| Dyspnea | 2 | 2017 | 10 | 0.070 |
Why?
|
| Cough | 2 | 2017 | 14 | 0.070 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2006 | 2 | 0.070 |
Why?
|
| Urban Population | 1 | 2008 | 257 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 237 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2006 | 115 | 0.060 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2004 | 1 | 0.060 |
Why?
|
| Deglutition Disorders | 4 | 2010 | 5 | 0.050 |
Why?
|
| Adolescent | 6 | 2010 | 2985 | 0.050 |
Why?
|
| Orchiectomy | 3 | 1996 | 6 | 0.050 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2021 | 17 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2021 | 30 | 0.050 |
Why?
|
| Consensus | 1 | 2021 | 62 | 0.050 |
Why?
|
| Urban Health | 1 | 2021 | 78 | 0.040 |
Why?
|
| Hemangiosarcoma | 1 | 2000 | 2 | 0.040 |
Why?
|
| Abdominal Neoplasms | 1 | 2000 | 3 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 2 | 1997 | 2 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2000 | 6 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2000 | 12 | 0.040 |
Why?
|
| HIV-1 | 1 | 2008 | 1260 | 0.040 |
Why?
|
| Esophageal Stenosis | 2 | 1996 | 2 | 0.040 |
Why?
|
| Retrospective Studies | 5 | 2006 | 799 | 0.040 |
Why?
|
| Thymoma | 1 | 1997 | 1 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 1997 | 1 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2000 | 131 | 0.040 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 1997 | 2 | 0.040 |
Why?
|
| Salivary Gland Neoplasms | 1 | 1997 | 4 | 0.040 |
Why?
|
| Liposarcoma | 1 | 1997 | 1 | 0.040 |
Why?
|
| Thigh | 1 | 1997 | 2 | 0.040 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1997 | 4 | 0.040 |
Why?
|
| Chest Pain | 1 | 2017 | 3 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2017 | 16 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2008 | 480 | 0.030 |
Why?
|
| Time Factors | 3 | 2008 | 507 | 0.030 |
Why?
|
| Carotid Body Tumor | 1 | 1995 | 1 | 0.030 |
Why?
|
| Glomus Jugulare Tumor | 1 | 1995 | 1 | 0.030 |
Why?
|
| Paraganglioma | 1 | 1995 | 2 | 0.030 |
Why?
|
| Radiation Injuries | 2 | 2010 | 2 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2004 | 370 | 0.030 |
Why?
|
| Infertility, Male | 1 | 1994 | 6 | 0.030 |
Why?
|
| Mass Screening | 1 | 1995 | 245 | 0.030 |
Why?
|
| Age Factors | 2 | 2008 | 370 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2004 | 171 | 0.020 |
Why?
|
| HIV Infections | 1 | 2008 | 5097 | 0.020 |
Why?
|
| Biopsy | 2 | 2000 | 38 | 0.020 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2008 | 4 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2008 | 12 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 26 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 107 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 1997 | 9 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 133 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2000 | 149 | 0.020 |
Why?
|
| Life Style | 1 | 2008 | 86 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2006 | 4 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 125 | 0.020 |
Why?
|
| Oncology Service, Hospital | 1 | 2006 | 3 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2006 | 20 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 1997 | 9 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 563 | 0.020 |
Why?
|
| Incidence | 1 | 2008 | 685 | 0.020 |
Why?
|
| Decision Making | 1 | 2006 | 53 | 0.020 |
Why?
|
| Prevalence | 1 | 2008 | 1192 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 61 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 2498 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2004 | 179 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 64 | 0.010 |
Why?
|
| Causality | 1 | 2000 | 7 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2000 | 19 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 63 | 0.010 |
Why?
|
| Child | 1 | 2006 | 2242 | 0.010 |
Why?
|
| Neutrons | 1 | 1997 | 2 | 0.010 |
Why?
|
| Photons | 1 | 1997 | 2 | 0.010 |
Why?
|
| Salivary Glands | 1 | 1997 | 3 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 1997 | 4 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1997 | 16 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1998 | 175 | 0.010 |
Why?
|
| Linear Models | 1 | 1997 | 83 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1996 | 3 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1996 | 11 | 0.010 |
Why?
|
| Dilatation | 1 | 1996 | 2 | 0.010 |
Why?
|
| Radiography | 1 | 1996 | 80 | 0.010 |
Why?
|
| Acute Disease | 1 | 1996 | 105 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1995 | 34 | 0.010 |
Why?
|
| Esophagus | 1 | 1995 | 2 | 0.010 |
Why?
|
| Fibrosis | 1 | 1995 | 11 | 0.010 |
Why?
|